Dongkook Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

15.46

P/S

1.00

EPS

1,073.25

Div Yield, %

1.10%

Shrs. gr., 5y

0.19%

Rev. gr., 5y

12.77%

Revenues

730.99b

+10.48%

Net income

47.18b

-10.82%

CFO

41.79b

-14.98%

Dividend

Dec 27, 2023180 KRW/sh

Earnings

Mar 12, 2025

Profile

DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durakinase, and Lorelin Depot injections; produces various natural product materials, such as black cohosh extract and magnolia extract comprises ETIZM and TECA; and natural herb medicines. In addition, it provides general and prescription-based drugs; medical devices; ETC and cosmetic products; and quasi drugs that include lipossol hydrocare bandage. DongKook Pharmaceutical Co., Ltd. also exports its products to approximately 40 countries, including Japan, Europe, Central and South America, and India. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

URL

http://www.dkpharm.co.kr/

IPO date

May 29, 2007

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	730,993,597 10.48%	661,647,492 11.35%	594,193,122 6.28%
Cost of revenue	590,766,050	517,228,159	463,721,479
Unusual Expense (Income)
NOPBT	140,227,547	144,419,333	130,471,644
NOPBT Margin	19.18%	21.83%	21.96%
Operating Taxes	11,966,256	13,875,730	16,837,187
Tax Rate	8.53%	9.61%	12.90%
NOPAT	128,261,291	130,543,603	113,634,457
Net income	47,175,203 -10.82%	52,895,927 5.07%	50,345,221 -9.98%
Dividends	(8,050,633)	(8,049,373)	(8,049,373)
Dividend yield	1.11%	1.08%	0.83%
Proceeds from repurchase of equity	(2,420,863)
BB yield	0.33%
Debt
Debt current	56,485,207	63,933,023	106,566,126
Long-term debt	24,215,521	27,448,968	13,687,325
Deferred revenue		920,000	875,000
Other long-term liabilities	11,989,428	8,000,405	9,189,938
Net debt	(121,759,274)	(122,475,634)	(130,833,394)
Cash flow
Cash from operating activities	41,792,951	49,158,510	44,246,516
CAPEX	(34,176,699)	(51,229,874)	(51,421,415)
Cash from investing activities	(52,390,667)	(20,753,121)	(45,822,183)
Cash from financing activities	(2,297,966)	(38,893,322)	32,431,741
FCF	107,203,963	72,781,013	53,315,424
Balance
Cash	94,159,871	107,104,759	169,929,494
Long term investments	108,300,131	106,752,866	81,157,351
Excess cash	165,910,322	180,775,251	221,377,189
Stockholders' equity	561,412,454	519,789,027	470,324,785
Invested Capital	498,956,644	437,850,026	380,140,704
ROIC	27.38%	31.92%	32.74%
ROCE	21.09%	23.17%	21.48%
EV
Common stock shares outstanding	44,731	44,724	44,719
Price	16,160.00 -2.65%	16,600.00 -23.85%	21,800.00 -25.47%
Market cap	722,851,942 -2.63%	742,414,167 -23.84%	974,868,532 -25.47%
EV	632,957,533	649,448,700	871,499,503
EBITDA	161,325,143	163,595,520	147,819,051
EV/EBITDA	3.92	3.97	5.90
Interest	5,867,708	4,319,783	2,883,086
Interest/NOPBT	4.18%	2.99%	2.21%